Alexandros Hatzimanolis
Overview
Explore the profile of Alexandros Hatzimanolis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Angelopoulou E, Androni X, Villa C, Hatzimanolis A, Scarmeas N, Papageorgiou S
Front Neurol
. 2025 Feb;
16:1534193.
PMID: 39980634
Identifying individuals at-risk for dementia is one of the critical objectives of current research efforts, highlighting the need for simple, cost-effective, and minimally invasive biomarkers. Mild behavioral impairment (MBI), characterized...
2.
Charisis S, Mourtzi N, Scott M, Ntanasi E, Mamalaki E, Hatzimanolis A, et al.
J Prev Alzheimers Dis
. 2025 Jan;
12(1):100018.
PMID: 39800457
Importance: Aging is accompanied by immune dysregulation, which has been implicated in Alzheimer's disease (AD) pathogenesis. Individuals who are genetically predisposed to elevated levels of proinflammatory mediators might be at...
3.
Angelopoulou E, Bougea A, Hatzimanolis A, Scarmeas N, Papageorgiou S
Cells
. 2024 Jul;
13(13.
PMID: 38995015
The emergence of sustained neuropsychiatric symptoms (NPS) among non-demented individuals in later life, defined as mild behavioral impairment (MBI), is linked to a higher risk of cognitive decline. However, the...
4.
Angelopoulou E, Koros C, Hatzimanolis A, Stefanis L, Scarmeas N, Papageorgiou S
Int J Mol Sci
. 2024 Mar;
25(5).
PMID: 38473892
The clinical features and pathophysiology of neuropsychiatric symptoms (NPSs) in dementia have been extensively studied. However, the genetic architecture and underlying neurobiological mechanisms of NPSs at preclinical stages of cognitive...
5.
Sampatakakis S, Mourtzi N, Charisis S, Mamalaki E, Ntanasi E, Hatzimanolis A, et al.
Curr Issues Mol Biol
. 2024 Jan;
46(1):934-947.
PMID: 38275674
The present study investigated the association of genetic predisposition for white matter hyperintensities (WMHs) with incident amnestic mild cognitive impairment (aMCI) or Alzheimer's disease (AD), as well as whether such...
6.
Angelopoulou E, Bougea A, Hatzimanolis A, Stefanis L, Scarmeas N, Papageorgiou S
Medicina (Kaunas)
. 2024 Jan;
60(1).
PMID: 38256375
Neuropsychiatric symptoms (NPS), including depression, anxiety, apathy, visual hallucinations, and impulse control disorders, are very common during the course of Parkinson's disease (PD), occurring even at the prodromal and premotor...
7.
Kosteletos I, Hatzimanolis A, Xenaki L, Ralli I, Dimitrakopoulos S, Vlahos I, et al.
Psychiatriki
. 2023 Oct;
35(1):17-25.
PMID: 37793035
Multiple recent studies have indicated that adverse psycho-traumatic experiences are particularly significant, if not the most significant, among the environmental factors that participate in the aetiology of schizophrenic spectrum disorders....
8.
Vlachos I, Selakovic M, Ralli I, Hatzimanolis A, Xenaki L, Dimitrakopoulos S, et al.
J Clin Med
. 2023 Jul;
12(13).
PMID: 37445295
Introduction: Clinical insight constitutes a useful marker of the progress and outcome of the First Episode of Psychosis (FEP), and lack of insight has been associated with more severe psychopathology,...
9.
Mamalaki E, Charisis S, Mourtzi N, Hatzimanolis A, Ntanasi E, Kosmidis M, et al.
Nutr Neurosci
. 2023 Mar;
27(3):289-299.
PMID: 36961750
The aim of the current study was to investigate whether genetic risk factors may moderate the association between adherence to the Mediterranean diet and AD incidence. The sample was drawn...
10.
Mourtzi N, Charisis S, Tsapanou A, Ntanasi E, Hatzimanolis A, Ramirez A, et al.
Alzheimers Dement
. 2023 Mar;
19(9):3794-3805.
PMID: 36895094
Introduction: We constructed a polygenic risk score (PRS) for β-amyloid (PRSAβ42) to proxy AD pathology and investigated its association with incident Alzheimer's disease (AD)/amnestic mild cognitive impairment (aMCI) and the...